Intraoperative Chemotherapy with a Novel Regimen Improved the Therapeutic Outcomes of Colorectal Cancer

Liu, Zhihua; Zou, Yifeng; Rong, Yuming; Shi, Xiaoshun; Li, Chen; Li, Chao; Tian, Yinghai; Lin, Hong-Cheng; Lee, Min; Weng, Jian; Liu, Ting; Li, Xiaomei; Li, Weipeng; Zhou, Xinke

doi:10.7150/jca.35450

Cited by 8 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy with CPT-11 also induces intestinal mucositis with the increased expression of proinflammatory cytokines regulated by NODs ( 31 ). CF alone does not inhibit tumor growth, but in combination with 5-FU, it increases the antitumor effect of 5-FU ( 32 ).…”

Section: Discussionmentioning

confidence: 99%

Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury

Huang

Gui

et al. 2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury

Huang

Gui

et al. 2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Chemotherapy with CPT-11 also induces intestinal mucositis with increased expression of proinflammatory cytokines regulated by NODs (29). CF alone does not inhibit tumor growth, but in combination with 5-FU, it increases the antitumor effect of 5-FU (30).…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy drugs induce different gut microbiota disorder pattern and NODs/RIP2/NF-κB signaling pathway activation that lead to different degrees of intestinal injury

Huang

Gui²,

Zhao

et al. 2022

Preprint

View full text Add to dashboard Cite

5-Fluorouracil (5-FU), oxaliplatin (L-OHP) ,etc .used chemotherapy drugs to treat colorectal cancer. chemotherapy is often accompanied by intestinal inflammation and gut microbiota disorder. The change of gut microbiota may lead to destruction of the intestinal barrier, which contributes to the severity of intestinal injury. There was no detailed comparison of intestinal injury and gut microbiota disorder among 5-FU, CPT-11, L-OHP and CF, which is not benefit for the development of targeted detoxification therapy after chemotherapy. A model of chemotherapy-induced intestinal injury in tumor-bearing mice was established by intraperitoneal injection of chemotherapy drugs at a clinically equivalent dose. 16S rDNA sequencing was used to detect gut microbiota. We found that 5-FU, CPT-11 and L-OHP caused intestinal injury, inflammatory cytokine secretion, and gut microbiota disorder. Importantly, we established a complex but clear network between the gut microbiota change pattern and intestinal damage degree induced by different chemotherapy drugs. L-OHP caused the most severe damage in intestine and disorder of gut microbiota, and showed considerable overlap of the microbiota change pattern with 5-FU and CPT-11. The phylogenetic investigation of communities by reconstruction of unobserved states, V1.0 analysis showed that the microbiota disorder pattern induced by 5-FU, CPT-11 and L-OHP was related to the NOD like signaling pathway. we detected the protein expression of the NODs/RIP2/NF-κB signaling pathway and found that L-OHP activated that pathway highest. By RDA/CCA analysis, Bifidobacterium, Akkermansia, Allobaculum, Catenibacterium, Mucispirillum, Turicibacter, Helicobacter, Proteus, Escherichia Shigella, Alloprevotealla, Vagococcus, etc. correlated with the NODs/RIP2/NF-κB signaling pathway, and influenced by chemotherapy drugs.

show abstract

“…Though intraoperative intraperitoneal chemotherapy as a new strategy to improve prognosis after R0 resection for CRC has been confirmed valid [ 18 ], further research is still needed to figure out whether it can prolong overall survival (OS) time, prevent peritoneal metastasis following the radical operation and any associated complications. We did the study with the aim of evaluating the effect and safety of intraoperative intraperitoneal chemotherapy on patients with colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer

et al. 2021

View full text Add to dashboard Cite

Background Colorectal cancer (CRC), the third most commonly diagnosed malignant carcinoma and the third most common cause of carcinoma-related mortality, continues to be a major international health problem. And approximately 33% of patients suffer from recurrence after radical surgery. Free malignant cell implanting in the peritoneum is generally accepted as one of the main reasons of such outcome. We did this present clinical study with the aim of evaluating the effects and safety of intraoperative intraperitoneal chemotherapy (IOC) on patients suffering from colorectal cancer, with hoping to find a novel, effective, and available approach to deal with malignant cell implanting during surgeries. Methods In total, 391 patients who went through colorectal radical surgery were considered eligible between June 1, 2017, and December 31, 2018. 220 patients were treated with surgery without IOC, while other 171 patients received surgery plus IOC. Clinical characteristics, operative findings, postoperative short-term outcomes, disease-free survival (DFS), and overall survival (OS) were compared between these above 2 groups in the selected population. Result The present research included 391 patients (251 men and 140 women) who underwent surgery without IOC (n = 171) or surgery plus IOC (n = 220), with a mean (SD) age of 60.4 (9.7) years in the surgery without IOC group and 60.6 (8.7) in the surgery plus IOC group (P=.85). No significant differences were witnessed between the two groups in surgery-related information and postoperative complications. It is worth noting that IOC independent of other factors was associated with a favor prognosis in CRC patients with stage II/III (HR 0.50, 95%CI 0.30–0.82, P=.006). Moreover, for patients with stage II colorectal carcinoma, DFS did not differ between two groups (P=.553, Kaplan-Meier log-rank), and OS was no exception. In stage III CRC patients, the estimated DFS rate for patients receiving IOC was 82.2% and patients without IOC was 66.4% after 3 years, which demonstrated that IOC was associated with a favorable prognosis in stage III patients (P=.012, Kaplan-Meier log-rank). Furthermore, the differences were still remained between the two groups when considering the influence about postoperative chemotherapy (P=.014, Kaplan-Meier log-rank). IOC can also significantly improve patients’ overall survival whether they get treatment with POC (P=.006, Kaplan-Meier log-rank; P=.025, Kaplan-Meier log-rank). Conclusions In the present study, we have found that surgery plus IOC generated a favorable prognosis for stage III CRC patients but not stage II without any side-effects when the dosage of lobaplatin was 0.1g/L. As a new, safe, and simple procedure, IOC therapy is easily performed—and does not require any special devices or techniques. Thus, IOC is a promising and exciting therapeutic strategy for patients with CRC.

show abstract

Intraoperative Chemotherapy with a Novel Regimen Improved the Therapeutic Outcomes of Colorectal Cancer

Cited by 8 publications

References 19 publications

Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury

Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury

Chemotherapy drugs induce different gut microbiota disorder pattern and NODs/RIP2/NF-κB signaling pathway activation that lead to different degrees of intestinal injury

Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer

Contact Info

Product

Resources

About